Kinase inhibitors and their targets discussed in this review Biology Diagrams
Kinase inhibitors and their targets discussed in this review Biology Diagrams This review aims to outline mitotic kinase inhibitors' roles as potential therapeutic targets and assess their suitability as a stand-alone clinical therapy or in combination with standard treatments for advanced-stage solid tumors, including triple-negative breast cancer (TNBC). Breast cancer poses a significant global health risk, with TNBC standing out as the most aggressive subtype
This was accomplished by combining CDK4/6i with additional CIN-inducing agents, including a bromodomain and extraterminal repeat (BET) inhibitor and mitotic kinase inhibitors. As the inhibition of many mitotic kinases is highly toxic, we identified Nima-related kinase 2 (NEK2) as a potential therapeutic target that could be combined with CDK4/6i.
Mitotic Inhibitors Biology Diagrams
Anti-mitotic therapies in cancer J Cell Biol. 2019 Jan 7;218(1) :10-11. doi Aurora Kinase B / antagonists & inhibitors Aurora Kinase B / genetics Aurora Kinase B / metabolism Neoplasms / drug therapy* Neoplasms / genetics Neoplasms / metabolism The development of mitotic kinase inhibitors came as an outgrowth of studies on the molecular mechanisms of the cell cycle in the 1990s [38-40], which promised the development of precise inhibitors of mitosis without the toxic sequelae of classical chemotherapeutics. Yet for all the initial excitement, mitotic kinase inhibitors have now been
Mitosis checkpoint kinase (CHK) inhibitors (including LY2603618) These agents act on the mitotic process, a proven target for anti-neoplastic therapy. It will be important for the development of these agents to evaluate the potential advantages over available mitotic inhibitors. It is likely that patient selection will hold a key to
Why Great Mitotic Inhibitors Make Poor Cancer Drugs Biology Diagrams
In prostate cancers, the abundance of the tumor suppressor PDCD4 is inversely correlated with response to the antiandrogen (also known as an androgen receptor inhibitor) enzalutamide. Zhang et al. found that PDCD4 is repressed by the mitotic kinase PLK1, which enabled the activity of cell survival pathways that are androgen independent. In
